Chapter 6 144 REFERENCES Dasgupta, A. (2007) ‘Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management’, Clinica Chimica Acta, pp. 1–13. doi: 10.1016/j.cca.2006.08.026. Dealberto, M. J. C. C. (2007) ‘Valproate-induced hyperammonaemic encephalopathy: Review of 14 cases in the psychiatric setting’, International Clinical Psychopharmacology, pp. 330–337. doi: 10.1097/ YIC.0b013e3281c61b28. Dols, A. et al. (2016) ‘Do current national and international guidelines have specific recommendations for older adults with bipolar disorder? A brief report’, International Journal of Geriatric Psychiatry, pp. 1295–1300. doi: 10.1002/gps.4534. Evans, M. D., Shinar, R. and Yaari, R. (2011) ‘Reversible dementia and gait disturbance after prolonged use of valproic acid’, Seizure, 20(6), pp. 509–511. doi: 10.1016/j.seizure.2011.02.009. Greenblatt, D. J., Sellers, E. M. and Koch-Weser, J. (1982) ‘Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations’, The Journal of Clinical Pharmacology, 22(5– 6), pp. 259–263. doi: 10.1002/j.1552-4604.1982.tb02671.x. Jansen, A. J. G. et al. (2012) ‘Therapeutic drug monitoring of free fraction valproic acid in patients with hypoalbuminaemia’, Netherlands Journal of Medicine, p. 329. Kodama, Y. et al. (2002) ‘Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy’, American Journal of Health-System Pharmacy, 59(9), pp. 835–840. doi: 10.1093/ajhp/59.9.835. De Maat, M. M. R., Van Leeuwen, H. J. and Edelbroek, P. M. (2011) ‘High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy’, Annals of Pharmacotherapy, 45(3). doi: 10.1345/aph.1P308. Naranjo, C. A. et al. (1981) ‘A method for estimating the probability of adverse drug reactions’, Clinical Pharmacology and Therapeutics, 30(2), pp. 239–245. doi: 10.1038/clpt.1981.154. Nasreddine, Z. S. et al. (2005) ‘The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment’, Journal of the American Geriatrics Society, 53(4), pp. 695–699. doi: 10.1111/j.1532-5415.2005.53221.x. Ng, F. et al. (2009) ‘The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments’, Bipolar Disorders, 11(6), pp. 559–595. doi: 10.1111/j.1399-5618.2009.00737.x. Reisberg, B. et al. (1982) ‘The global deterioration scale for assessment of primary degenerative dementia’, American Journal of Psychiatry, 139(9), pp. 1136–1139. doi: 10.1176/ajp.139.9.1136. Sajatovic, M., Madhusoodanan, S. and Coconcea, N. (2005) ‘Managing bipolar disorder in the elderly: Defining the role of the newer agents’, Drugs and Aging, pp. 39–54. doi: 10.2165/00002512200522010-00003. Sriboonruang, T. et al. (2011) ‘The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: Analysis based on routine therapeutic drug monitoring data’, Journal of Clinical Psychopharmacology, 31(1), pp. 115–119. doi: 10.1097/ JCP.0b013e318203b405. Wallenburg, E. et al. (2017) ‘Monitoring protein-unbound valproic acid serumconcentrations in clinical practice’, Therapeutic Drug Monitoring, 39(3), pp. 269–272. doi: 10.1097/FTD.0000000000000405.
RkJQdWJsaXNoZXIy MTk4NDMw